Last checked at 1 May 2024 07:00
聽
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
聽
DHSC application for summary judgment dismissed
聽
Paris, France, and Eastleigh and Manchester, UK - 1 May 2024 - Following the announcement on 19 April 2024, Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, notes the judgment by Mrs Justice Jefford following the Pre-Trial Review heard on 30 April 2024. Mrs Justice Jefford has dismissed the application by the Department of Health and Social Care ("DHSC") for summary judgment.
聽
The Pre-Trial Review has now concluded, and the trial hearing has been listed to commence on 10 June 2024, and finish on 4 July 2024. The Company expects the court to reserve judgment, meaning that the outcome of the trial will not be known on 4 July 2024.
聽
聽
聽
Contacts
聽
Novacyt SA | https://novacyt.com/investors | |||
Lyn Rees, Chief Executive Officer | 聽Via Walbrook PR | |||
Steve Gibson, Chief Financial Officer聽 聽 聽 | ||||
SP Angel Corporate Finance LLP (Nominated Adviser and Broker) | +44 (0)20 3470 0470 | |||
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) | ||||
Deutsche Numis (Joint Broker) | +44 (0)20 7260 1000 | |||
Freddie Barnfield / Duncan Monteith / Michael Palser | ||||
Allegra Finance (French Listing Sponsor) R茅mi Durgetto / Yannick Petit | 聽+33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com | |||
Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Paul McManus / Phillip Marriage / Alice Woodings | +44 (0)20 7933 8780 or novacyt@walbrookpr.com +44 (0)7796 794 663 / +44 (0)7980 541 893 聽+44 (0)7867 984 082 / +44 (0)7407 804 654 | |||
聽
About Novacyt Group (www.novacyt.com)
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.
聽
The Company is divided into three business segments:
聽
Clinical | Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: 路 Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests 路 Precision Medicine: DPYD genotyping assay 路 Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel 聽 |
Instrumentation | Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: 路 Ranger庐 Technology: automated DNA sample preparation and target enrichment technology MyGo: real-time quantitative PCR (qPCR) instruments 聽 |
Research Use Only | Range of services for the research industry: 路 Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry 路 Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) |
聽
Novacyt is headquartered in V茅lizy in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").
聽
For more information, please refer to the website: www.novacyt.com
聽